Payment overview · 2025
General Payments
$99.08
5 reported records · 4 companies
Healthcare provider profile · identity verified
Michael H Gordon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CLARKS SUMMIT, PA · NPI 1043288897
Verified facts
What the public records show
CMS Open Payments records show Michael H Gordon, MD received $99.08 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.89 | 36.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.77 | 29.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.32 | 19.5% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $15.10 | 15.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $99.08 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.89 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.89 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 619 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 545 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 532 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 485 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 340 | 76 |
| Omeprazole | Omeprazole | 287 | 68 |
| Metformin Hcl | Metformin Hcl | 277 | 69 |
| Losartan Potassium | Losartan Potassium | 276 | 67 |
| Lisinopril | Lisinopril | 274 | 64 |
| Alprazolam | Alprazolam | 259 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 46 |
| Furosemide | Furosemide | 214 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 45 |
| Gabapentin | Gabapentin | 201 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 18 |
| Jardiance | Empagliflozin | 167 | 26 |
| Eliquis | Apixaban | 156 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 32 |
| Simvastatin | Simvastatin | 142 | 39 |
| Ezetimibe | Ezetimibe | 126 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 53 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 117 | 89 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 24 |
| Potassium Chloride | Potassium Chloride | 100 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 21 |
| Januvia | Sitagliptin Phosphate | 96 | 17 |
| Lorazepam | Lorazepam | 95 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 20 |
| Tramadol Hcl | Tramadol Hcl | 83 | 18 |
| Cefdinir | Cefdinir | 79 | 60 |
| Clonazepam | Clonazepam | 79 | 14 |
| Famotidine | Famotidine | 77 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 15 |
| Carvedilol | Carvedilol | 72 | 16 |
| Azithromycin | Azithromycin | 64 | 54 |
| Warfarin Sodium | Warfarin Sodium | 63 | 11 |
| Allopurinol | Allopurinol | 62 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 60 | 32 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Ozempic | Semaglutide | 57 | 12 |
| Glimepiride | Glimepiride | 56 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 35 |
| Finasteride | Finasteride | 52 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 39 |
| Methylprednisolone | Methylprednisolone | 47 | 36 |
| Spironolactone | Spironolactone | 46 | 14 |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Amoxicillin | Amoxicillin | 43 | 29 |
| Indapamide | Indapamide | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Prednisone | Prednisone | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 11 |
| Meloxicam | Meloxicam | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 20 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Acetazolamide Er | Acetazolamide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Lipitor | Atorvastatin Calcium | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $99.08 · 5 records | Amgen Inc. | LOREEV XR, OTEZLA, Ozempic, REPATHA, Rybelsus | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error